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OBJECTIVES: 1) To evaluate the compliance with drug treatment in patients with metabolic syndrome. 2) To determine associa-
tion between access to and use of medicines, as well as the level of knowledge of cardiovascular risk factors and compliance. 
INTRODUCTION: Low compliance has been one of the greatest challenges for the successful treatment of chronic diseases. 
Although this issue has been widely studied in patients with isolated hypertension, diabetes and dyslipidemia, compliance studies 
involving patients with these concomitant diseases or with metabolic syndrome diagnosis are scarce. 
METHODS: This was a cross-sectional study involving patients who have been diagnosed with metabolic syndrome accord-
ing to the IDF criteria. Patients were being treated in a Health-Medical School Center bound to the Public Brazilian Healthcare 
System. This study was conducted in two phases. Phase I was characterized by analyzing medical records and Phase II involved 
interviewing the patients. A variation of the Morisky-Green Test was used to evaluate compliance. Compliance was the dependent 
variable and the independent variables included access to medicines, the use of medicines and the level of knowledge concerning 
cardiovascular risk factors.
RESULTS: Two hundred and forty-three patients were identified as being eligible for Phase II, and 75 were included in the study. 
The average level of compliance was 5.44 points (standard deviation of 0.68), on a scale ranging from 1.00 to 6.00 points. There 
was no statistically meaningful association between independent variables and compliance. The level of patient knowledge of diet 
and dyslipidemia was considered to be low.
CONCLUSIONS: Patients involved in this study exhibited a high level of compliance with drug treatment. Further research is 
needed to better elucidate the compliance behavior of patients who have been diagnosed with metabolic syndrome. 
KEYWORDS: Adherence; Hypertension; Diabetes; Abdominal obesity; Drug utilization.
INTRODUCTION
In recent years metabolic syndrome has aroused universal 
interest from the scientific community1 as well as healthcare 
managers.2 This condition is highly prevalent in both 
developed3 and emerging countries.4 It involves both young 
and elder persons3,5 and it is associated with an increased 
risk of diabetes, cardiovascular morbidity and mortality.6-7 
The main goal of treatment for metabolic disease is to reduce 
cardiovascular risk.8 Although lifestyle change is the first line 
of therapy, many patients require integrated drug treatment.8,9 
Even in the absence of the clinical manifestation of 
atherosclerotic cardiovascular disease or diabetes, any person 
with metabolic syndrome should undergo Framingham risk 
scoring.10,11
Low patient compliance has been one of the greatest 
challenges for success in the treatment of chronic diseases 
such as hypertension, dyslipidemia and diabetes, even when 
they appear as isolated entities.12,13 In practice, the treatment 
of metabolic syndrome implies the sum of difficulties 
usually found in monitoring each one of its components. 
According to the World Health Organization, patient 
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compliance with treatment is defined as the extent to which 
a person’s behavior – taking medication, following a diet 
and/or executing lifestyle changes – corresponds with the 
recommendations from the healthcare provider.14
Although this issue has been widely studied in patients 
with isolated hypertension, diabetes and dyslipidemia,15-17 
compliance studies involving patients with these concomitant 
diseases or with metabolic syndrome diagnosis are scarce. To 
assess patient compliance with drug treatment for metabolic 
syndrome, a cross-sectional study was performed. This 
study also had the objective of determining the association 
between access to and the use of medicines, as well as the 
level of knowledge of cardiovascular risk factors and patient 
compliance with drug treatment.
METHODS
This cross-sectional study included patients who had 
been diagnosed with metabolic syndrome and who were 
being treated in a Health-Medical School Center attached to 
the Public Brazilian Healthcare System (SUS).
This study was conducted in two phases. Phase I was 
characterized by the analysis of medical records, aimed 
at identifying those patients who showed evidence of 
metabolic syndrome according to the International Diabetes 
Federation (IDF) criteria:18 waist circumference – ethnicity 
specific values (males ≥ 90 cm and for females ≥ 80 cm) as a 
measure of central obesity, plus any two of the following: (a) 
raised triglyceride levels (≥ 150 mg/dl, or specific treatment 
for this lipid abnormality); (b) reduced HDL-cholesterol 
levels (< 40 mg/dl in males and < 50 mg/dl in females, or 
specific treatment for this lipid abnormality); (c) raised blood 
pressure (systolic ≥ 130 mmHg or diastolic ≥ 85 mmHg, or 
treatment of previously diagnosed hypertension); (d) raised 
plasma glucose (fasting plasma glucose ≥ 100 mg/dl, or 
previously diagnosed type 2 diabetes). If the Body Mass 
Index was > 30 kg/m2, central obesity was assumed and 
waist circumference was not measured.18 
In Step 1, patients who were diagnosed with hypertension 
and/or diabetes were identified. Subsequently (Step 2), 
patient data concerning all components of metabolic 
syndrome was collected, according to the availability of 
medical records. This step considered the diagnosis specified 
on the medical records, the prescription of medicines for the 
treatment of each component of metabolic syndrome and 
finally the results of clinical and laboratory tests. 
In Step 3, obese and overweight patients were selected 
according to their Body Mass Index (BMI). In Step 4, data 
records were analyzed regarding the presence of other 
metabolic syndrome components in the overweight or obese 
patients. Among patients identified in Step 4, those who 
were between 18 and 70 years of age and on drug treatment 
for at least one of the metabolic syndrome components were 
selected to participate in Phase II. Those who had totally or 
partially restricted verbal communication (specified in the 
medical records) were excluded.
In Phase II, patients who were identified in Phase I and 
showed evidence of metabolic syndrome were called in to be 
interviewed to confirm their diagnosis, evaluate compliance 
with drug treatment and determine the associations between 
the analyzed variables. 
Interviews were scheduled by phone and conducted 
personally, using a structured questionnaire addressing the 
following aspects: (i) socio-demographic patient profile; 
(ii) access to and use of medicines; (iii) knowledge of 
cardiovascular risk factors based on the study by Kahn et al.19; 
(iv) assessment of patient compliance with drug treatment using 
the Measure Treatment Adherence (MTA) Scale developed by 
Delgado and Lima.20 Drug treatment encompassed integrated 
management with antihypertensive, antidiabetic and antilipemic 
agents. The MTA Scale, a variation of the Morisky-Green 
Test with seven questions, was used to assess patient behavior 
patterns associated with the use of medicines.20 The MTA 
Scale consists of the following questions: (1) Have you ever 
forgotten to take your medicines?; (2) Were you careless at 
times about taking your medicines?; (3) When you felt better, 
did you sometimes stop taking your medicines?; (4) Sometimes, 
if you felt worse, did you stop taking your medicines?; (6) 
Have you ever discontinued treatment because you ran out of 
pills?; (7) Have you ever stopped taking your medicines for any 
reason other than a medical advisory? The MTA Scale allows 
answers from “always” to “never,” with scores ranging from 
1 to 6 points. The highest values indicate the highest level of 
compliance with drug treatment.20 
During the interviews, to confirm diagnosis, patients 
were asked about the time of diagnosis of each metabolic 
syndrome component and the treatment recommendation. 
The following anthropometric measurements were also 
performed: weight, height and waist circumference. To 
measure weight in kilograms and height in meters, an 
anthropometric balance was used (FilizollaTM, Campo 
Grande, MS, Brazil) with barefoot patients, wearing light 
clothes and looking at the horizon. The waist circumference, 
in centimeters, was measured on bare skin, mid-distance 
between the bottom of the rib cage and the top of the iliac 
crest 21 using an inelastic tape.
Patient compliance was the dependent variable evaluated. 
The following variables were considered independent: 
- Variables related to access to medicines (mode of acqui-
sition of medicines, difficulty in getting prescriptions 
filled and expense of medicines compared to total family 
income); 
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- Variables related to the use of medicines (number of 
medicines per day, number of tablets per day and daily 
dose frequency, responsibility for managing medicines 
and interference of patients’ daily routine);
- Level of knowledge about cardiovascular risk factors.
Statistical analysis was performed by the Spearman 
coefficient and the Kruskal-Wallis or Mann-Whitney non-
parametric tests. It was established that p < 0.05 would be 
the limit for statistical significance and the software used 
was SPSS 15.0 for Windows (SPSS Inc., USA).
Analysis of medical records began in March 2007 and 
lasted two months. Interviews were conducted from May 
to July 2007. 
This research was approved by the Committee of Ethics 
on October 30, 2006 (Protocol Number: 395). Only those 
patients who provided their written consent took part in this 
study.
RESULTS
Patient Characteristics
Table 1 summarizes the results of each step of medical 
record analysis and patient selection. 
Among the 243 identified patients, 83 (34.2%) scheduled 
an appointment for this study. The other 160 (65.8%) patients 
could not schedule an appointment for the following reasons: 
104 (42.8%) could not be contacted due to difficulties with 
phone calls, 55 (22.6%) did not agree to participate and one 
patient had died (0.41%). Of the 83 scheduled patients, 8 did 
not attend their appointment. As a result, 75 patients with 
confirmed metabolic syndrome diagnosis were included in 
this study. Table 2 presents the characteristics of the 243 
identified patients.
Social-demographic characteristics. Among the 75 
included patients, 41 (54.66%) were women. Average 
Table 2 - Clinical characteristics of 243 identified patients with evidence of metabolic syndrome, according to medical 
records
Identified patients who scheduled an 
appointment to research (n=83)
Identified patients who did not schedule an 
appointment to research (n=160)
n Mean SD n Mean SD p
Weight(kg) 83 82.7 16.7 160 81.3 16.2 0.530
Height (cm) 83 159.6 9.2 160 157.3 8.9 0.061
BMI* (kg/m2) 83 32.6 5.3 160 32.8 5.7 0.792
Triglycerides (mg/dl)** 75 201.2 129.7 125 213.2 133.0 0.536
HDL-cholesterol (mg/dl)** 13 47.0 7.7 14 47.4 8.8 0.905
Men 06 41.5 8.4 03 44.3 7.6 0.699
Women 07 51.7 2.1 11 48.6 10.6 0.491
SBP (mmHg)† 71 144.0 24.6 139 143.5 20.8 0.878
DBP (mmHg) † 71 87.7 13.5 139 88.5 12.5 0.671
Glycemic level (mg/dl)‡ 76 168.1 59.4 143 182.3 69.0 0.132
SD: Standard deviation. Statistically significant: p < 0.05. * Body Mass Index based on weight and height measurements from medical records from the 
last physician evaluation; **Triglycerides and HDL-cholesterol values from medical records from the last laboratory blood tests; † Systolic and Diastolic 
Blood Pressure descriptive values from medical records from the last physician evaluation; ‡ Descriptive value of glycemic levels from medical records 
from the most recent laboratory blood tests.
Table 1 - Results of each step of medical record analysis and 
patient selection
Step 1 – Electronic patients database analysis
550 records of diabetic and / or hypertensive patients
Step 2 – Data collection from medical records
483 medical records available
Step 3 – Selection of overweight or obese patients
56 medical records without information about obesity
60 patients with BMI* < 25 kg/m2
367 overweight or obese patients (BMI ≥ 25 kg/m2 or obesity diagnosis 
specified on medical notes)
Step 4 – Data analysis of other metabolic syndrome components
200 patients with diagnosis of MS† (BMI ≥ 30 kg/m2 + 2 components)
144 patients with evidence of MS (132 with 25 ≤ BMI ≤ 29.9 kg/m2 and 
12 with obesity diagnosis from medical notes + 2 components)
In 23 cases it was not possible to suppose presence of MS with available 
data.
Step 5 – Other inclusion and exclusion criteria checked
101 patients excluded (1 without drug treatment and 100 older than 70 
years) 
243 patients identified for Phase II
* BMI = Body Mass Index. † MS = Metabolic Syndrome.
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participant age was 63 years (minimum: 42 years; maximum: 
70 years). There were 46 (61.3%) married patients, 44 
(58.6%) patients were housewives or retired persons and 37 
(61.3%) patients were living with their spouse and children. 
With regard to level of education, 35 (46.7%) patients had 
4 years or less of elementary studies. The majority, i.e., 45 
(60.0%) participants, consisted of patients with a low family 
income (from R$415.00 to R$2,075.00 per months; R$ 1.00 
= US$ 1.60). Regarding race, 37 (49.3%) patients considered 
themselves white, 31 (41.3%) were African-descendants, 
4 (5.33%) were Asian, 1 (1.33%) was indigenous and 2 
(2.68%) did not answer this question.
Clinical characteristics. All 75 patients presented 
with a high waist circumference along with two more 
cardiovascular risk factors. Clinical characteristics of the 
patients are shown in Tables 3, 4 and 5. 
Characteristics related to access and use of medicines. 
All patients received their medicines from the Public 
Brazilian Healthcare System, completely (42 patients; 
56.0%) or partially (33 patients, 44.0%). Thirty-four 
Table 3 - Descriptive values of anthropometric measurements of the 75 included patients, according to medical records and 
at the time of inclusion
Anthropometric Measurement Medical records(n=75) Inclusion (n=75)
Mean SD Mean SD
Weight (kg) 83.1 17.4 84.6 17.3
Height (cm) 161.0 9.5 160.2 9.5
BMI (kg/m2) 32.3 5.4 32.8 5.3
Waist Circumference (cm)
 Men (n=34) NA NA 112.0 12.2
 Women (n=41) NA NA 102.7 12.3
SD: Standard deviation. BMI: Body Mass Index. NA: Not available.
Table 4 - Mean and standard deviation of clinical and laboratory tests of patients included in this study. Period of time be-
tween last medical records and at the time of patient inclusion in the study
Medical records ∆T (month)*
n Mean SD Mean SD
SBP (mmHg)** 64 143.4 23.6 8.6 3.6
DBP (mmHg)** 64 86.7 12.2 8.6 3.6
Glycemic level (mg/dl) † 68 165.4 59.6 10.7 4.7
Triglycerides (mg/dl) ‡ 68 205.0 132.2 15.0 7.0
HDL-cholesterol (mg/dl) ‡ 12 46.7 8.0 12.5 4.9
Men 6 41.5 8.4 - -
Women 6 51.8 2.3 - -
SD: Standard deviation. *∆T: Period of time, in months, between last medical records and at the time of patient inclusion in the study. **Systolic and Dia-
stolic Blood Pressure values from medical records from the last physician evaluation. † Glycemic level value from medical records from the most recent 
laboratory blood tests. ‡ Triglyceride and HDL-cholesterol values from medical records from the last laboratory blood tests.
Table 5 - Distribution of frequencies of metabolic syndrome compo-
nents, according to medical records of the 75 included patients
Metabolic syndrome components Number of patients
(n=75)
%
HT + DM + Elevated TG 41 54.7
HT + DM 25 33.3
HT + Glucose Intolerance 3 4.0
HT + Glucose Intolerance + 
Elevated TG
2 2.7
HT + DM + Elevated TG + Re-
duced HDL
2 2.7
HT + Elevated TG + Reduced 
HDL
1 1.3
DM + Elevated TG 1 1.3
HT: Hypertension diagnosis based on medical notes and prescription of 
antihypertensive drugs; DM: diagnosis of diabetes mellitus based on medical 
notes and prescription of antidiabetic agents; Elevated TG: triglycerides ≥ 
150 mg/dl according to medical records from the last laboratory blood tests; 
Reduced HDL: HDL-cholesterol ≤ 40 mg/dl (for men) and ≤ 50 mg/dl (for 
women) according to medical records from the last laboratory blood tests.
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(45.3%) patients said that they had no expense related to 
their medication, and 26 (34.7%) spent up to 10% of their 
total family income on medicines. Regarding the level of 
difficulty in getting their prescriptions filled, 67 (89.3%) 
patients said that they considered this an easy task. Table 
6 presents the descriptive values of the number of different 
prescribed medicines, the number of tablets and dose 
frequency. Table 7 shows the number of patients for each 
category of prescribed drugs.
Seventy (93.3%) patients had the responsibility of 
managing their medication by themselves and 67 (89.3%) 
patients believed that taking medicines did not disturb their 
daily routine (56 patients) or that it disturbed their routine 
only a little (11 patients). 
Characteristics related to the level of knowledge 
of cardiovascular risk factors. Among the 75 patients 
evaluated, 35 (46.6%) exhibited a good level of knowledge 
about cardiovascular risk factors (correct answers ≥ 75%), 
while 24 (32.0%) patients had only a moderate level of 
knowledge (50% < correct answers < 74.9%). Ten (13.4%) 
patients exhibited a low level of knowledge (25% < correct 
answers < 49.9%) and 6 others (8.00%) demonstrated a very 
low level of knowledge (correct answers ≤ 24.9%). Figure 
1 shows the average distribution of percentages of correct 
answers for each cardiovascular risk factor assessed. 
PATIENT COMPLIANCE AND ASSOCIATION 
BETWEEN VARIABLES
Patients showed high compliance with their drug 
treatment, with an average score of 5.44 points (SD = 0.68). 
The association analysis between independent variables 
and compliance gave the following results:
- Variables related to access to medicines: mode of acqui-
sition of medicines (completely or partially from SUS; 
Mean ± SD: 5.42 ± 0.79 vs. 5.47 ± 0.52; p = 0.876), 
Table 7 - Number and percentage of patients by prescribed 
drug category
Prescribed drugs Number of patients 
(n=75)
%
Antihypertensive agents 74 98.6
Oral hypoglycemic agents 69 92.0
Acetylsalicylic acid 23 30.6
Insulin 16 21.3
Antilipemic agents 13 17.3
Antiulcer agents 12 16.0
Central Nervous System drugs 8 10.6
Thyroid hormones 5 6.8
Antiglaucomatous agents 1 1.3
Table 6 - Descriptive values of medicines prescribed to the 75 included patients
Variable Mean Standard deviation Median Min Max
No. of medicines 4.2 1.9 4.0 1.0 9.0
No. of tablets/day 7.0 4.5 6.0 1.0 24.0
Dose frequency (times/day) 2.2 0.6 2.0 1.0 3.0
Figure 1 - Patient knowledge about cardiovascular risk factors: % average of correct answers of 75 patients 
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degree of difficulty in getting prescriptions filled (mod-
erate or easy; Mean ± SD: 5.69 ± 0.43 vs. 5.41 ± 0.70 ; 
p = 0.124) and expense of medicines compared to total 
family income (0% of the family income, up to 10% 
of family income, and > 10% of family income; Mean 
± SD: 5.48 ± 0.38 vs. 5.29 ± 1.01 vs. 5.78 ± 0.26; p = 
0.136). None of these variables showed an association 
with compliance with drug treatment. 
- Variables related to the use of medicines: there was 
no association between the number of medicines (p = 
0.976), number of tablets/day (p = 0.964) and daily dose 
frequency (p = 0.913) and compliance. Similarly, there 
was no association between responsibility for managing 
medication and compliance (patient or caregiver; Mean ± 
SD: 5.43 ± 0.69 vs. 5.57 ± 0.55; p = 0.560). Patients who 
said that taking medicines has disturbed their daily rou-
tine did not show degree of compliance significantly dif-
ferent from those who negatively answered this question 
(Mean ± SD: 5.29 ± 0.61 vs. 5.57 ± 0.35; p = 0.115).
- The level of knowledge about cardiovascular risk factors: 
there was no association with patient compliance with 
drug treatment, even when each cardiovascular risk factor 
was considered on its own.
DISCUSSION 
In the present study, all data were collected from the 
medical records of 483 hypertensive and/or diabetic patients 
who were registered in a Health-Medical School Center 
associated with the Public Brazilian Healthcare System 
(SUS). There was a lack of data to identify patients with 
metabolic syndrome, such as waist circumference and 
HDL-cholesterol levels. This suggests that the concept of 
metabolic syndrome is not well established in the clinical 
practice at the Health-Medical School Center where this 
study was performed. As a matter of fact, there are many 
controversies about this condition that are related to the 
existence of several definitions for metabolic syndrome, its 
pathophysiological mechanism, its value as a good predictor 
of diabetes or cardiovascular disease and even whether or not 
it is truly a syndrome.22-26 
Compliance with drug treatment evaluation may be 
performed by direct methods (directly observed therapy, 
measurement of the level of medicines or metabolites in 
blood and measurement of biological markers in blood) and 
indirect methods (assessment of patient clinical response, 
rates of prescription refills, pill counts, electronic medication 
monitors and information collected from health professionals 
or patients, such as questionnaires and self-reports).27 No 
method is considered to be the gold standard.20,27 Direct 
methods are objective and accurate, but expensive.27 
Indirect methods are easy to use, but subjectivity may be a 
disadvantage.14 
Evaluating compliance by assessing patient clinical 
response supposes a direct association between compliance 
and the expected clinical results. Patient health problems 
may be resolved or be controlled for reasons other than 
compliance with drug treatment.20 Patients may also 
be compliant with drug treatment but still not show the 
desired result. Clinical results may be used as a measure 
of compliance when the treatment is related to a specific 
clinical result, for example, glycemic or blood pressure 
levels. However, some authors consider the occurrence of the 
“effect of toothbrush”, i.e., the patient is compliant with the 
treatment only immediately before visiting the doctor.20 
Questionnaires and self-reports are susceptible to 
distortion. Patients generally want to please their physicians 
and will often say what they think their doctor wants to 
hear.20,27 Aiming at overcoming these biases and obtaining 
a method that is easy to use and suitable for different 
situations, the Morisky-Green Test was developed.28 It is 
composed of four questions that allow dichotomous answers 
(“yes” or “no”). Patients are considered to be compliant 
with treatment when they answer negatively all questions. 
According to the authors, considering negative answers 
as the valid ones should reduce the problem of patients 
overestimating compliance. 28 
In this study, compliance was evaluated using a variation 
of the Morisky-Green Test28 that had the advantage of 
making alternatives to answers in the Likert Scale possible. 
This makes the test significantly more sensible, allowing for 
the detection of situations of non-adherence.20 
A high compliance level with drug treatment was 
verified. This is not in accordance with other compliance 
studies using the same types of drugs. Studies with 
antihypertensive agents showed compliance levels between 
50% and 70%. During the first year of treatment, from 
16% to 50% of patients gave up the treatment.14 Regarding 
antilipemic agents, it is estimated that only 50% of patients 
who were being treated with statins continue to use their 
medication after six months, and only 30% to 40% are 
taking them after one year.29 Additionally, a study that 
used the Morisky-Green Test to evaluate compliance with 
diabetes treatment showed that 51% of diabetic patients were 
considered to be non-adherent.30
Therefore, it is important to take into consideration the 
possibility that the patients who decided to participate in 
this study were naturally compliant. In this case, statistically 
significant differences between blood glucose and pressure 
levels should have been observed. Patients who scheduled 
an appointment for the research should have presented with 
better blood glucose and pressure levels than those who 
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did not. However, this was not confirmed. Another relevant 
point to be considered is the possibility that patients may 
overestimate their compliance.
Compliance is a multidimensional phenomenon determined 
by the interplay of five sets of factors: socioeconomic 
factors; therapy-related factors; condition-related factors; 
patient-related factors; and healthcare team and system-
related factors.14 Although socioeconomic factors have not 
consistently been found to be an independent predictor of 
compliance, low socioeconomic status may put patients in the 
position of having to choose between competing priorities.14 
In this scenario, the cost of medicine is a key issue for 
compliance levels.31 Financial restrictions may lead patients to 
total or partial interruption of their treatments.32 The scarcity of 
medicines is a factor even with the free distribution of essential 
medicines, including antihypertensive and oral hypoglycemic 
agents from the Public Brazilian Health System. In this study, 
34.7% of patients spent up to 10% of their family income on 
medicine. 
Considering that 66.7% of patients had low incomes, 
it was expected that even low expense for medicines 
would influence compliance levels. However, there was no 
association between the level of expense of medicine and 
compliance. It is important to consider the limited number of 
patients and the absence of another comparative group.
Regarding therapy-related factors, some studies showed 
that compliance with drug treatment decreases as the 
number of different medicines, the number of pills and the 
dosage frequency33 increases. Nevertheless, this study found 
no association between these variables and compliance. 
Patient-related factors, such as knowledge and beliefs 
about their disease, motivation to manage it and expectations 
regarding the outcome of treatment, interact in ways not yet 
fully understood to influence compliance behavior.14 This 
study did not find an association between knowledge of 
cardiovascular risk factors and compliance. 
Together, these findings suggest the existence of a 
specific compliance behavior profile that is characteristic 
of the studied patients, but independent of the analyzed 
variables. It may be related to the multidisciplinary approach 
the patient adopted at the Health-Medical School Center 
where the research was performed. However, this hypothesis 
was not tested in this study. The multidisciplinary approach 
has been recognized as an effective contributory factor for 
improving compliance levels.27,31 In spite of this approach, 
its application on a daily basis demands continual effort, 
self-discipline and teamwork by health professionals.31 As 
these challenges are met, the multidisciplinary approach is 
considered to be part of the health system’s daily routine, 
and elevated compliance levels are possible.
This study also identified a lack of knowledge of 
cardiovascular risk factors, mainly diet and dyslipidemia. 
Knowledge about disease or treatment does not guarantee 
patient compliance,34 but it is an important factor in active 
patient participation in decisions that involve his/her 
health condition.35 From this point of view, there may be 
an opportunity to promote cardiovascular risk reduction. 
The adoption of educational strategies that improve patient 
knowledge of cardiovascular risk factors may give them an 
incentive to actively participate in their treatment and to 
make treatment success more tangible. This may be the first 
step in effectively introducing diet and regular practice of 
physical activity in daily routines, once these activities are 
associated with significant clinical improvements.36 Finally, 
better knowledge of cardiovascular risk factors may lead to 
more rational utilization of financial resources.
CONCLUSIONS
Patients with metabolic syndrome who were being treated 
in a Health-Medical School Center with antihypertensive, 
antilipemic and antidiabetic agents, have demonstrated a 
high level of drug compliance. There were no statistically 
significant associations between access to and use of 
medicines and level of knowledge of cardiovascular risk 
factors and compliance. Patients included in this study also 
demonstrated a low knowledge of diet and dyslipidemia; this 
may have implications for non-drug treatment and for the 
reduction of cardiovascular risk. However, this hypothesis 
needs further investigation. More research is needed to 
confirm if the high level of compliance found in this study 
is characteristic of patients treated in a Health-Medical 
School Center in comparison with patients treated in other 
public or private healthcare centers. Additionally, it might be 
especially elucidative to have comparative studies enrolling 
patients with metabolic syndrome as well as other patient 
groups with diagnoses of isolated hypertension, diabetes 
and dyslipidemia.
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